$1.57
1.26% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

MacroGenics, Inc. Stock price

$1.57
+0.18 12.95% 1M
-1.71 52.13% 6M
-1.68 51.69% YTD
-2.69 63.15% 1Y
-2.41 60.55% 3Y
-24.24 93.92% 5Y
-30.77 95.15% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.02 1.26%
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

Key metrics

Market capitalization $99.05m
Enterprise Value $-17.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.24
EV/Sales (TTM) EV/Sales -0.11
P/S ratio (TTM) P/S ratio 0.64
P/B ratio (TTM) P/B ratio 1.25
Revenue growth (TTM) Revenue growth 255.31%
Revenue (TTM) Revenue $154.05m
EBIT (operating result TTM) EBIT $-99.45m
Free Cash Flow (TTM) Free Cash Flow $-72.40m
Cash position $154.14m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 1.31
EV/Sales forward negative
Short interest 11.08%
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a MacroGenics, Inc. forecast:

2x Buy
25%
6x Hold
75%

Analyst Opinions

8 Analysts have issued a MacroGenics, Inc. forecast:

Buy
25%
Hold
75%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
154 154
255% 255%
100%
- Direct Costs 23 23
50% 50%
15%
131 131
367% 367%
85%
- Selling and Administrative Expenses 60 60
33% 33%
39%
- Research and Development Expense 163 163
3% 3%
106%
-92 -92
47% 47%
-60%
- Depreciation and Amortization 7.47 7.47
12% 12%
5%
EBIT (Operating Income) EBIT -99 -99
46% 46%
-65%
Net Profit -56 -56
140% 140%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
14 days ago
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.
Neutral
GlobeNewsWire
19 days ago
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 341
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today